Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.
Read the full article on the original site.
Read Full Article